Switch to:
Also traded in: Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.63
OTCPK:EPGNF's Cash-to-Debt is ranked higher than
91% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. OTCPK:EPGNF: 2.63 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:EPGNF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.73  Med: 1006.24 Max: 11742.5
Current: 2.63
1.73
11742.5
Equity-to-Asset 0.58
OTCPK:EPGNF's Equity-to-Asset is ranked higher than
58% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. OTCPK:EPGNF: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:EPGNF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.66 Max: 0.98
Current: 0.58
0.39
0.98
Debt-to-Equity 0.49
OTCPK:EPGNF's Debt-to-Equity is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. OTCPK:EPGNF: 0.49 )
Ranked among companies with meaningful Debt-to-Equity only.
OTCPK:EPGNF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 0.74
Current: 0.49
0
0.74
Debt-to-EBITDA -0.66
OTCPK:EPGNF's Debt-to-EBITDA is ranked lower than
99.99% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. OTCPK:EPGNF: -0.66 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OTCPK:EPGNF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.66  Med: -0.13 Max: 0
Current: -0.66
-0.66
0
Piotroski F-Score: 3
Altman Z-Score: 1.32
Beneish M-Score: -2.94
WACC vs ROIC
-8.40%
-617.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -378.45
OTCPK:EPGNF's Operating Margin % is ranked lower than
84% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. OTCPK:EPGNF: -378.45 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:EPGNF' s Operating Margin % Range Over the Past 10 Years
Min: -1166.79  Med: -509.55 Max: -239.86
Current: -378.45
-1166.79
-239.86
Net Margin % -332.22
OTCPK:EPGNF's Net Margin % is ranked lower than
83% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. OTCPK:EPGNF: -332.22 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:EPGNF' s Net Margin % Range Over the Past 10 Years
Min: -1173.92  Med: -493.42 Max: -239.98
Current: -332.22
-1173.92
-239.98
ROE % -80.13
OTCPK:EPGNF's ROE % is ranked lower than
85% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. OTCPK:EPGNF: -80.13 )
Ranked among companies with meaningful ROE % only.
OTCPK:EPGNF' s ROE % Range Over the Past 10 Years
Min: -140.91  Med: -85.82 Max: -52.91
Current: -80.13
-140.91
-52.91
ROA % -54.29
OTCPK:EPGNF's ROA % is ranked lower than
80% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. OTCPK:EPGNF: -54.29 )
Ranked among companies with meaningful ROA % only.
OTCPK:EPGNF' s ROA % Range Over the Past 10 Years
Min: -92.61  Med: -65.44 Max: -45.73
Current: -54.29
-92.61
-45.73
ROC (Joel Greenblatt) % -1385.42
OTCPK:EPGNF's ROC (Joel Greenblatt) % is ranked lower than
88% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. OTCPK:EPGNF: -1385.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:EPGNF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2903.81  Med: -1490.54 Max: -313.33
Current: -1385.42
-2903.81
-313.33
3-Year Revenue Growth Rate 15.90
OTCPK:EPGNF's 3-Year Revenue Growth Rate is ranked higher than
77% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. OTCPK:EPGNF: 15.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:EPGNF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -45.4  Med: -9.3 Max: 17.9
Current: 15.9
-45.4
17.9
3-Year EBITDA Growth Rate 2.90
OTCPK:EPGNF's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. OTCPK:EPGNF: 2.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:EPGNF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.2  Med: -9.1 Max: 63.1
Current: 2.9
-30.2
63.1
3-Year EPS without NRI Growth Rate -3.80
OTCPK:EPGNF's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. OTCPK:EPGNF: -3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:EPGNF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.7  Med: -12.7 Max: 62.6
Current: -3.8
-27.7
62.6
GuruFocus has detected 5 Warning Signs with Epigenomics AG OTCPK:EPGNF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:EPGNF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with EPGNF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Epigenomics AG does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:PMD, OTCPK:ODYY, NAS:VRML, XKRX:950140, OSTO:CRAD B, NAS:TRIB, NAS:CEMI, XPAR:ALMDT, NZSE:PEB, TSE:7707, XKRX:086040, LSE:AGL, TSE:9707, NAS:ONVO, XTER:LIO1, OCSE:BIOPOR, XKRX:084650, ASX:VHT, XKRX:217600, NAS:FLGT » details
Traded in other countries:ECXV.Germany, 0QXH.UK,
Headquarter Location:Germany
Epigenomics AG is a molecular diagnostics company. The Company is engaged in developing and commercializing the proprietary products in vitro diagnostic test for screening, early detection and diagnosis of cancer.

Epigenomics AG was founded as a limited liability company (GmbH) in 1998. The Company develop and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer.

Ratios

vs
industry
vs
history
PB Ratio 8.36
EPGNF's PB Ratio is ranked lower than
90% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. EPGNF: 8.36 )
Ranked among companies with meaningful PB Ratio only.
EPGNF' s PB Ratio Range Over the Past 10 Years
Min: 0.67  Med: 7.45 Max: 24.21
Current: 8.36
0.67
24.21
PS Ratio 37.75
EPGNF's PS Ratio is ranked lower than
89% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. EPGNF: 37.75 )
Ranked among companies with meaningful PS Ratio only.
EPGNF' s PS Ratio Range Over the Past 10 Years
Min: 4.6  Med: 25.74 Max: 62.44
Current: 37.75
4.6
62.44
EV-to-EBIT -9.22
EPGNF's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. EPGNF: -9.22 )
Ranked among companies with meaningful EV-to-EBIT only.
EPGNF' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.7  Med: -6.8 Max: 1.1
Current: -9.22
-26.7
1.1
EV-to-EBITDA -9.51
EPGNF's EV-to-EBITDA is ranked lower than
99.99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. EPGNF: -9.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
EPGNF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.7  Med: -7.2 Max: 1.2
Current: -9.51
-28.7
1.2
EV-to-Revenue 34.86
EPGNF's EV-to-Revenue is ranked lower than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. EPGNF: 34.86 )
Ranked among companies with meaningful EV-to-Revenue only.
EPGNF' s EV-to-Revenue Range Over the Past 10 Years
Min: -6.9  Med: 25.3 Max: 64.8
Current: 34.86
-6.9
64.8
Current Ratio 2.00
EPGNF's Current Ratio is ranked lower than
58% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. EPGNF: 2.00 )
Ranked among companies with meaningful Current Ratio only.
EPGNF' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.61 Max: 11.77
Current: 2
1.35
11.77
Quick Ratio 1.97
EPGNF's Quick Ratio is ranked lower than
51% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. EPGNF: 1.97 )
Ranked among companies with meaningful Quick Ratio only.
EPGNF' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.57 Max: 11.74
Current: 1.97
1.15
11.74
Days Inventory 313.88
EPGNF's Days Inventory is ranked lower than
79% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. EPGNF: 313.88 )
Ranked among companies with meaningful Days Inventory only.
EPGNF' s Days Inventory Range Over the Past 10 Years
Min: 18.59  Med: 136.49 Max: 313.88
Current: 313.88
18.59
313.88
Days Sales Outstanding 23.93
EPGNF's Days Sales Outstanding is ranked higher than
70% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. EPGNF: 23.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
EPGNF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.93  Med: 74.36 Max: 195.32
Current: 23.93
23.93
195.32
Days Payable 1.00
EPGNF's Days Payable is ranked higher than
97% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. EPGNF: 1.00 )
Ranked among companies with meaningful Days Payable only.
EPGNF' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 597.36 Max: 2101.25
Current: 1
1
2101.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.10
EPGNF's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. EPGNF: -20.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EPGNF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.2  Med: -17.7 Max: 35.2
Current: -20.1
-34.2
35.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.43
EPGNF's Price-to-Net-Cash is ranked lower than
77% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.00 vs. EPGNF: 14.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EPGNF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.07  Med: 13.06 Max: 295.5
Current: 14.43
1.07
295.5
Price-to-Net-Current-Asset-Value 11.87
EPGNF's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. EPGNF: 11.87 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EPGNF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.94  Med: 12.42 Max: 93
Current: 11.87
0.94
93
Price-to-Tangible-Book 8.90
EPGNF's Price-to-Tangible-Book is ranked lower than
82% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. EPGNF: 8.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EPGNF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 7.57 Max: 31.79
Current: 8.9
0.89
31.79
Price-to-Median-PS-Value 1.47
EPGNF's Price-to-Median-PS-Value is ranked lower than
64% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. EPGNF: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EPGNF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.96 Max: 2.23
Current: 1.47
0.23
2.23
Earnings Yield (Greenblatt) % -10.85
EPGNF's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. EPGNF: -10.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EPGNF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1744.7  Med: -12.9 Max: 826.3
Current: -10.85
-1744.7
826.3

More Statistics

Revenue (TTM) (Mil) $2.87
EPS (TTM) $ -0.42
Beta-1.25
Short Percentage of Float0.00%
52-Week Range $4.19 - 8.25
Shares Outstanding (Mil)24.01

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 6 1
EPS ($) -0.65 -0.38
EPS without NRI ($) -0.65 -0.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}